Overview

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

Status:
Not yet recruiting
Trial end date:
2024-10-30
Target enrollment:
Participant gender:
Summary
This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation